Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Nov 28;23(44):7813-7817.
doi: 10.3748/wjg.v23.i44.7813.

Advances in endoscopic balloon therapy for weight loss and its limitations

Dinesh Vyas  1 , Kaivalya Deshpande  2 , Yagnik Pandya  3
Affiliations
Editorial

Advances in endoscopic balloon therapy for weight loss and its limitations

Dinesh Vyas et al. World J Gastroenterol. .

Abstract

The field of medical and surgical weight loss is undergoing an explosion of new techniques and devices. A lot of these are geared towards endoscopic approaches rather than the conventional and more invasive laparoscopic or open approach. One such recent advance is the introduction of intrgastric balloons. In this article, we discuss the recently Food and Drug Administration approved following balloons for weight loss: the Orbera™ Intragastric Balloon System (Apollo Endosurgery Inc, Austin, TX, United States), the ReShape® Integrated Dual Balloon System (ReShape Medical, Inc., San Clemente, CA, United States), and the Obalon (Obalon® Therapeutics, Inc.). The individual features of each of these balloons, the method of introduction and removal, and the expected weight loss and possible complications are discussed. This review of the various balloons highlights the innovation in the field of weight loss.

Keywords: Endoscopic balloons; Gastric balloons; Obalon; Orbera; Reshape; Weight loss.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: All authors have no stated conflicts of interest related to this publication.

Figures

Figure 1
Figure 1
The history and development of Intragastric balloons: Depicting the timeline of developed interventions and devices involved for treatment of surgical and medical weight loss. Approvals by FDA and region specific utilizations are highlighted, illustrating the dynamic progression of techniques in the field. FDA: Food and Drug Administration.
See this image and copyright information in PMC

References

    1. Ponce J. Impact of Different Surgical Techniques on Outcomes in Laparoscopic Sleeve Gastrectomies: First Report from the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) Ann Surg. 2016 Epub ahead of print. - PubMed
    1. Benjamin SB, Maher KA, Cattau EL Jr, Collen MJ, Fleischer DE, Lewis JH, Ciarleglio CA, Earll JM, Schaffer S, Mirkin K. Double-blind controlled trial of the Garren-Edwards gastric bubble: an adjunctive treatment for exogenous obesity. Gastroenterology. 1988;95:581–588. - PubMed
    1. Ponce J, Quebbemann BB, Patterson EJ. Prospective, randomized, multicenter study evaluating safety and efficacy of intragastric dual-balloon in obesity. Surg Obes Relat Dis. 2013;9:290–295. - PubMed
    1. Dalton S. The dietitians' philosophy and practice in multidisciplinary weight management. J Am Diet Assoc. 1998;98:S49–S54. - PubMed
    1. Gleysteen JJ. A history of intragastric balloons. Surg Obes Relat Dis. 2016;12:430–435. - PubMed

Publication types

MeSH terms